Back to top
more

Esperion Therapeutics (ESPR)

(Delayed Data from NSDQ)

$2.13 USD

2.13
5,355,541

+0.04 (1.91%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $2.12 -0.01 (-0.47%) 7:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (147 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for ESPR

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Esperion Therapeutics, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 82 167 259 305 202
Receivables 48 34 23 0 0
Notes Receivable 0 0 0 0 0
Inventories 66 35 34 16 0
Other Current Assets 5 11 12 25 10
Total Current Assets 201 247 329 346 212
Net Property & Equipment 0 0 1 1 1
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 0 0 50 0 0
Total Assets 206 248 382 353 214
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 32 23 18 52 29
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 63 41 37 32 29
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 60 28 17 7 7
Total Current Liabilities 156 92 73 94 66
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 1 0 0
Convertible Debt 262 260 258 179 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 240 219 246 173 127
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 661 572 579 449 195
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 1,149 1,071 964 798 715
Retained Earnings -1,549 -1,340 -1,106 -839 -695
Other Equity 0 0 0 0 0
Treasury Stock 55 55 55 55 0
Total Shareholder's Equity -455 -324 -197 -96 20
Total Liabilities & Shareholder's Equity 206 248 382 353 214
Total Common Equity -455 -324 -197 -96 20
Shares Outstanding 118.20 73.60 60.80 27.80 27.30
Book Value Per Share -3.85 -4.40 -3.24 -3.46 0.73

Fiscal Year End for Esperion Therapeutics, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 82 115 138 162
Receivables NA 48 43 41 36
Notes Receivable NA 0 0 0 0
Inventories NA 66 51 46 39
Other Current Assets NA 5 9 7 13
Total Current Assets NA 201 218 232 251
Net Property & Equipment NA 0 0 0 0
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 0 0 0 0
Deposits & Other Assets NA 0 0 0 0
Total Assets NA 206 221 235 252
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 32 26 25 17
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 63 54 44 39
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 60 57 38 39
Total Current Liabilities NA 156 138 107 95
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 262 261 261 260
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 230 237 225
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 661 631 607 581
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 1,149 1,138 1,135 1,127
Retained Earnings NA -1,549 -1,493 -1,452 -1,402
Other Equity NA 0 0 0 0
Treasury Stock NA 55 55 55 55
Total Shareholder's Equity NA -455 -410 -372 -330
Total Liabilities & Shareholder's Equity NA 206 221 235 252
Total Common Equity 0 -455 -410 -372 -330
Shares Outstanding 185.00 118.20 106.90 106.90 76.50
Book Value Per Share 0.00 -3.85 -3.84 -3.48 -4.31